Gaining the Upper Hand
Measuring antiretroviral drug accumulation in the brain with MALDI-MSI to inform the best therapeutic avenue for HIV-associated neurocognitive disorder
Jonathan James | | Quick Read
Thanks to recent advances in antiretroviral (ARV) therapy, the life expectancy of HIV patients is now almost equal to that of the general population – at least in more developed nations. But, as life expectancy continues to increase, long term HIV-associated complications, such as HIV-associated neurocognitive disorder (HAND), represent a growing health concern (1). The pathology of HAND is underscored by an accumulation of HIV particles in the central nervous system; over time, the disorder prevents sufferers from carrying out basic tasks and eventually results in death. But which ARV drugs are likely to be most effective?
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Analytical Scientist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.